Keyphrases
Adjuvant Therapy
100%
Stage III Colon Cancer
100%
Oxaliplatin-induced Neuropathy
100%
Celecoxib
57%
Treatment Duration
42%
Common Terminology Criteria for Adverse Events (CTCAE)
42%
Vitamin B6
42%
Adjusted Odds Ratio
28%
Physical Activity
28%
Oxaliplatin
28%
Difference in Mean
28%
Neuropathy
28%
Body Mass Index
14%
Clinical Trials
14%
Multivariate Analysis
14%
Diabetes
14%
Prospective Observational Study
14%
Chemotherapy
14%
High Body Mass Index
14%
Type 1 Diabetes Mellitus (T1DM)
14%
Clinical Factors
14%
Patients with Diabetes
14%
Leucovorin
14%
Random Assignment
14%
Treatment Cycle
14%
Baseline BMI
14%
Fluorouracil
14%
Timing Resolution
14%
MET-minutes
14%
Oxaliplatin Chemotherapy
14%
Interactive Association
14%
Medicine and Dentistry
Mediator
100%
Adjuvant Therapy
100%
Colon Carcinoma
100%
Oxaliplatin-Induced Peripheral Neuropathy
100%
Body Mass Index
57%
Celecoxib
57%
Adverse Event
42%
Treatment Duration
42%
Oxaliplatin
42%
Pyridoxine
42%
Neuropathy
28%
Physical Activity
28%
Odds Ratio
28%
Clinical Trial
14%
Diabetes
14%
Observational Study
14%
Diabetes Mellitus
14%
Patient with Diabetes
14%
Fluorouracil
14%
Folinic Acid
14%
Multivariate Analysis
14%
Pharmacology, Toxicology and Pharmaceutical Science
Colon Carcinoma
100%
Oxaliplatin-Induced Peripheral Neuropathy
100%
Celecoxib
57%
Adverse Event
42%
Oxaliplatin
42%
Pyridoxine
42%
Chemotherapy
28%
Neuropathy
28%
Clinical Trial
14%
Observational Study
14%
Diabetes Mellitus
14%
Folinic Acid
14%
Fluorouracil
14%
Neuroscience
Adjuvant Therapy
100%
Oxaliplatin
100%
Neuropathy
100%
Body Mass Index
40%
Celecoxib
40%
Pyridoxine
30%
Diabetes Mellitus
10%
Fluorouracil
10%
Folinic Acid
10%
Immunology and Microbiology
Mediator
100%
Colon
100%
Body Mass
66%
Physical Activity
66%